Genenta Science S.p.A.
GNTANasdaqHealthcare · Biological Products, (No Diagnostic Substances) · L6 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Nuzzo MarcoActivist (13D)May 5, 2026
- Pierluigi ParacchiPassive (13G)Jan 27, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6,135 | 1.0 | -53.9% |
| Apr 30, 2026 | 13,319 | 1.0 | -78.7% |
| Apr 15, 2026 | 62,619 | 1.5 | -53.0% |
| Mar 31, 2026 | 133,286 | 1.0 | +195.0% |
| Mar 13, 2026 | 45,179 | 1.3 | -38.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.